An update on the management of chronic lymphocytic leukaemia

Karen W L Yee; Susan M. O'Brien; Francis J. Giles

doi:10.1517/14656566.5.7.1535

An update on the management of chronic lymphocytic leukaemia

Karen W L Yee, Susan M. O'Brien, Francis J. Giles^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a 'cure'. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 2004

Original language	English (US)
Pages (from-to)	1535-1554
Number of pages	20
Journal	Expert Opinion on Pharmacotherapy
Volume	5
Issue number	7
DOIs	https://doi.org/10.1517/14656566.5.7.1535
State	Published - Jul 2004

Keywords

Alemtuzumab
Chemotherapy
Chronic lymphocytic leukaemia
Cladribine
Fludarabine
Nucleoside analogues
Pentostatin
Rituximab

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

Access to Document

10.1517/14656566.5.7.1535

Cite this

@article{6198245380ba490288b787fc0cb295bd,

title = "An update on the management of chronic lymphocytic leukaemia",

abstract = "Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a 'cure'. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 2004",

keywords = "Alemtuzumab, Chemotherapy, Chronic lymphocytic leukaemia, Cladribine, Fludarabine, Nucleoside analogues, Pentostatin, Rituximab",

author = "Yee, {Karen W L} and O'Brien, {Susan M.} and Giles, {Francis J.}",

year = "2004",

month = jul,

doi = "10.1517/14656566.5.7.1535",

language = "English (US)",

volume = "5",

pages = "1535--1554",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - An update on the management of chronic lymphocytic leukaemia

AU - Yee, Karen W L

AU - O'Brien, Susan M.

AU - Giles, Francis J.

PY - 2004/7

Y1 - 2004/7

N2 - Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a 'cure'. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 2004

AB - Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a 'cure'. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 2004

KW - Alemtuzumab

KW - Chemotherapy

KW - Chronic lymphocytic leukaemia

KW - Cladribine

KW - Fludarabine

KW - Nucleoside analogues

KW - Pentostatin

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=3543110363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543110363&partnerID=8YFLogxK

U2 - 10.1517/14656566.5.7.1535

DO - 10.1517/14656566.5.7.1535

M3 - Review article

C2 - 15212604

AN - SCOPUS:3543110363

SN - 1465-6566

VL - 5

SP - 1535

EP - 1554

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 7

ER -

An update on the management of chronic lymphocytic leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this